Adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of remission (timeframe not reported) ‐ Symptoms‐guided diet · Patients with active Crohn's disease
It is very uncertain whether intervention diet changes induction of remission (timeframe not reported) ‐ Symptoms‐guided diet compared with control diet (very low certainty).
1 finding from 1 review
Health‐related quality of life (timeframe not reported) ‐ IBDQ ‐ Symptoms‐guided diet · Patients with active Crohn's disease
1 finding from 1 review
QoL · Patients with active Crohn's disease
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
OutcomesAnalysis 1.4 · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Failure to achieve clinical remission · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical remission (high certainty).
1 finding from 1 review
Intervention not reported
Failure to achieve clinical response (70‐point response) · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical response (70‐point response) (high certainty).
1 finding from 1 review
Intervention not reported
Failure to achieve clinical response (100‐point response) · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical response (100‐point response) (high certainty).
1 finding from 1 review
Intervention not reported
Endoscopic response · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (QoL) Inflammatory Bowel Disease Questionnaire (IBDQ) (scale: 32 to 224; higher score = better QoL) · Patients with active Crohn's disease
1 finding from 1 review
Intervention not reported
Adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in withdrawals due to adverse events (low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Certolizumab pegol probably leads to higher clinical remission compared with placebo (moderate certainty).
1 finding from 1 review
Clinical response · Patients with active Crohn's disease
Certolizumab pegol probably leads to higher clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce remission at 10 weeks · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) probably leads to lower failure to induce remission at 2 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100 point reduction) · Patients with active Crohn's disease
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in failure to induce clinical response at 6 weeks compared with placebo (low certainty).
1 finding from 1 review
Faliure to induce clinical response at 8 weeks · Patients with active Crohn's disease
Two infusions of natalizumab (300 mg or 3 mg/kg) may leads to lower faliure to induce clinical response at 8 weeks compared with placebo (low certainty).
1 finding from 1 review